Healthcare Industry News: Transdermal
News Release - June 20, 2007
Novagali Pharma Strengthens its Executive ManagementEVRY, France, June 20 (HSMN NewsFeed) -- Novagali Pharma, an emerging pharmaceutical company specialized in ophthalmology, announces today the appointment of Sylvie Elia-Foeillet as Vice President of Pharmaceutical Affairs and Genevieve Garrigos as Vice President of Human Resources and Communication.
Sylvie Elia-Foeillet has a significant experience of pharmaceutical and regulatory affairs. As an house resident holding a pharmaceutical degree, Sylvie started her career at Altana where she was in charge of product registration. She then headed regulatory affairs for Laboratoires Lundbeck being also temporary Responsible Pharmacist. In 2004, she joined Daiichi Sankyo France in quality of Director of Pharmaceutical Affairs and Qualified Person. In this position, she was in charge of all pharmaceutical affairs including product registration and follow-up with the Health Authorities. Sylvie is member of the editorial steering committee of the AFAR, the French Association of Regulatory Affairs. She now joins Novagali to structure and head the department of Pharmaceutical Affairs.
Genevieve Garrigos, Doctor of Pharmacy and graduate of the executive MBA of HEC, began her career at L'Oreal group holding various positions including marketing export Director of Vichy brand before joining Lavipharm as Vice President of Cosmetic Division. She then integrated Ethypharm group where she was successively Vice President Business Development of Ethymed, a subsidiary company specialized in Transdermal patchs, then Vice President Communication and Human Resources, and member of the Management Committee of the group. She accompanied the communication and image building of Ethypharm for the preparation of the IPO on Euronext. Genevieve collaborated with Novagali Pharma since 2005 as a consultant.
These recruitments follow the nomination of Philippe Garcia at the position of Chief Financial Officer of Novagali Pharma, and confirm the decision of the company to reinforce its management team and to continue its strategic turn into a fully integrated pharmaceutical company.
"We are delighted to welcome Sylvie who brings us her experience of product market authorization which we will soon face for the commercialization of our products", explained Jerome Martinez, President of Novagali Pharma who adds "the expertise of Genevieve in terms of institutional communication and management of Human Resources in the pharmaceutical sector is a great asset while Novagali Novagali Pharma has doubled its staff within the last 12 months, and pass at the higher speed as regards development".
Specialized in ophthalmology, Novagali Pharma is positioned on highly promising markets such as dry eye and glaucoma as well as on rare and severe diseases such as vernal keratoconjunctivitis with Vekacia®, a medicine dedicated to this condition for which the company has received orphan drug designation in both Europe and USA. According to VisionGain, the ophthalmic market was valued at US$ 10.5 billion in 2006, with a CAGR over 11%.
About Novagali Pharma: www.novagali.com
Novagali Pharma SA is an emerging ophthalmic pharmaceutical company based in the Genopole biocluster in Evry, France, that develops innovative products for all segments of the eye. Thanks to its proprietary technology platforms Novasorb® and Eyeject®, the company has developed a broad pipeline of innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia®, an orphan product for treatment of vernal keratoconjunctivitis; Cationorm®, a CE marking product for dry eye relief; and Nova22007, a product for the treatment of moderate-to-severe dry eye syndrome. Founded in 2000, the firm has raised a total amount of Euro 44 million in 3 series of financing and currently has 38 employees.
Source: Novagali Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.